HomeMarketsEarningsNovo Nordisk (NVO) Stock Rallies After Ozempic Trial Success For Kidney Problems
00:00
00:00
05:45
Novo Nordisk (NVO) Stock Rallies After Ozempic Trial Success For Kidney Problems

Novo Nordisk (NVO) Stock Rallies After Ozempic Trial Success For Kidney Problems

Novo Nordisk (NVO) rallies after Ozempic trial success for kidney problems. The trial included 3,500+ people with Type 2 Diabetes with two-thirds of patients at high risk of chronic kidney disease progress. NVO stopped the Ozempic trial early after positive results for kidney issues. Caroline Woods discusses this news. Tune in to find out more about the stock market today.

Morning Trade Live

11 Oct 2023

SHARE

ON AIR
4:00 pm
Fast Market
education
5:00 am
Your First Trade
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
The Wrap
REPLAY
7:00 am
Fast Market
REPLAY
8:00 am
Next Gen Investing
REPLAY
9:00 am
Market Overtime
REPLAY
education
9:30 am
Inside the Mind of a Trader
REPLAY
education
10:00 am
Inside the Mind of a Trader
REPLAY
education
10:30 am
Inside the Mind of a Trader
REPLAY
11:00 am
Market Overtime
REPLAY
12:00 pm
Morning Movers
1:00 pm
Morning Trade Live
3:00 pm
Trading 360
ON AIR
4:00 pm
Fast Market
5:00 pm
Next Gen Investing
6:00 pm
The Watch List
7:00 pm
Market On Close
8:30 pm
Market Overtime
REPLAY
9:00 pm
Fast Market
REPLAY
10:00 pm
Next Gen Investing
REPLAY
11:00 pm
The Wrap
REPLAY
12:00 am
Market Overtime
REPLAY
12:30 am
Market Overtime
REPLAY
1:00 am
The Wrap
REPLAY
2:00 am
Market Overtime
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY

Schwab Network's Newsletters

Daily insights for every investor